The estimated Net Worth of Cavan M. Redmond is at least 530 千$ dollars as of 24 June 2022. Mr. Redmond owns over 10,000 units of Oncocyte stock worth over 374,675$ and over the last 12 years he sold OCX stock worth over 0$. In addition, he makes 155,102$ as Independent Chairman of the Board at Oncocyte.
Sign up
Mr. Redmond OCX stock SEC Form 4 insiders trading
Cavan has made over 2 trades of the Oncocyte stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of OCX stock worth 31,000$ on 24 June 2022.
The largest trade he's ever made was buying 40,000 units of Oncocyte stock on 16 March 2022 worth over 47,600$. On average, Cavan trades about 4,167 units every 8 days since 2012. As of 24 June 2022 he still owns at least 120,863 units of Oncocyte stock.
You can see the complete history of Mr. Redmond stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Cavan Redmond biography
Cavan M. Redmond serves as Independent Chairman of the Board of the Company. Since 2014, Mr. Redmond has served as Partner for Zarsy, LLC. Mr. Redmond served as Chief Executive Officer of WebMD from May 2012 until May 2013. From August 2011 until May 2012, Mr. Redmond served as Group President, Animal Health, Consumer Healthcare and Corporate Strategy of Pfizer Inc., a pharmaceutical company. He served as Pfizer’s Group President, Animal Health, Consumer Healthcare, Capsugel and Corporate Strategy from December 2010 until August 2011 and as its Senior Vice President and Group President, Pfizer Diversified Businesses from October 2009 until December 2010. Prior to Pfizer’s acquisition of Wyeth, a pharmaceutical company, Mr. Redmond served as President, Wyeth Consumer Healthcare and Animal Health Business. Before that, he held the positions of President, Wyeth Consumer Healthcare from December 2007 until May 2009 and served on Wyeth Parmaceuticals’ Executive Leadership Team. At Wyeth, Mr. Redmond served as General Manager and Executive Vice President of Wyeth Bioparhma which grew into a leading global biotech company under his leadership. Mr. Redmond also served as a director of Lineage Cell Therapeutics, Inc. from February 2018 through July 2019 and has served on the boards of directors of The Wistar Institute of Anatomy and Biology and the Arthritis Foundation.
What is the salary of Cavan Redmond?
As the Independent Chairman of the Board of Oncocyte, the total compensation of Cavan Redmond at Oncocyte is 155,102$. There are 4 executives at Oncocyte getting paid more, with Ronald Andrews having the highest compensation of 2,102,210$.
How old is Cavan Redmond?
Cavan Redmond is 59, he's been the Independent Chairman of the Board of Oncocyte since 2018. There are 8 older and 1 younger executives at Oncocyte. The oldest executive at Oncocyte Corporation is Dr. Michael D. West Ph.D., 68, who is the Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc..
What's Cavan Redmond's mailing address?
Cavan's mailing address filed with the SEC is C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE, CA, 92618.
Insiders trading at Oncocyte
Over the last 9 years, insiders at Oncocyte have traded over 16,389,842$ worth of Oncocyte stock and bought 56,056,405 units worth 102,313,246$ . The most active insiders traders include Partners, L.P.Broadwood Cap...、Cell Therapeutics, Inc. Lin...、Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of 3,382,106$. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth 10,001$.
What does Oncocyte do?
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
What does Oncocyte's logo look like?
Complete history of Mr. Redmond stock trades at Pfizer、Oncocyte
Oncocyte executives and stock owners
Oncocyte executives and other stock owners filed with the SEC include:
-
Ronald Andrews,
President, Chief Executive Officer, Director -
Lyndal Hesterberg,
Chief Scientific Officer -
Mitchell Levine,
Chief Financial Officer -
Ronald A. Andrews Jr.,
CEO, Pres & Director -
Cavan Redmond,
Independent Chairman of the Board -
Andrew Last,
Independent Director -
Andrew Arno,
Independent Director -
Melinda Griffith,
Independent Director -
Bob Yedid,
Investor Relations -
Douglas Ross,
Chief Medical Officer -
Padma Sundar,
Senior Vice President - Marketing and Market Access -
Tony Kalajian,
Senior Vice President, Chief Accounting Officer -
Albert Parker,
Chief Operating Officer -
Dr. Michael D. West Ph.D.,
Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. -
Dr. Ekkehard Schutz M.D., Ph.D.,
Chief Technology Officer -
Robert S. Seitz,
Head of Immune Oncology -
Li Yu,
VP, Controller & Principal Accounting Officer -
Gisela A. Paulsen,
Chief Operating Officer -
Sara Riordan,
Director of Medical Education -
Dr. Michael D. West,
Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. -
Dr. Douglas T. Ross M.D., Ph.D.,
Chief Science Officer -
William Annett,
Advisor -
Gisela Paulsen,
Former President and COO -
Vida Investments, Llc Kamen...,
-
Karen B. Chapman,
Vice President of Research -
Alfred D Kingsley,
Director -
Don M Bailey,
Director -
William Annett,
President and CEO -
Michael D West,
Director -
Kristine C. Mechem,
VP of Marketing -
Partners, L.P.Broadwood Cap...,
-
Anish M. John,
Chief Financial Officer -
Aditya P. Mohanty,
Director -
Cell Therapeutics, Inc. Lin...,
-
James Yang Liu,
Sr Dir., Cntlr, PAO, Int PFO -
Jennifer L. Carter,
Director -
Li Yu,
VP Cntrllr/Prncpl Acctng Offcr -
Partners, L.P.Bradsher Neal...,
-
Lou Silverman,
Director -
Josh Riggs,
CEO and President -
John Peter Gutfreund,
-
Andrea S. James,
Chief Financial Officer